FDA approves Behring prostate cancer test:
This article was originally published in Clinica
Executive Summary
The FDA has cleared Behring Diagnostics's Opus PSA assay for use in measuring prostate specific antigen in serum. The assay is used with the company's Opus analysers to detect persistent or metastatic disease in patients who have received treatment for prostate cancer.